Merck & Co., Inc., Rahway, N.J., USA Financial Highlights Package Third Quarter 2025 Table of Contents Table 1: GAAP P&L....................................................................................1 Table 1a: GAAP P&L – Current Year and Prior Year by Quarter.................2 Table 2a: GAAP to Non-GAAP Reconciliation 3Q25 and Sept YTD 25.......3 Table 2b: GAAP to Non-GAAP Reconciliation 3Q24 and Sept YTD 24.......4 Table 3: Sales - Current Year and Prior Year by Quarter...........................5 Table 3a: Sales – U.S. / International 3Q25.................................................6 Table 3b: Sales – U.S. / International Sept YTD 25.....................................7 Table 3c: Sales – Pharmaceutical Geographic Split....................................8 Table 4: Other (Income) Expense .............................................................9 -- 1 of 10 -- Sales 17,276 $ 16,657 $ 4% 48,611 $ 48,544 $ 0% Costs, Expenses and Other Cost of sales 3,855 4,080 -6% 10,831 11,365 -5% Selling, general and administrative 2,633 2,731 -4% 7,835 7,952 -1% Research and development 4,234 5,862 -28% 11,903 13,354 -11% Restructuring costs 47 56 -16% 676 258 * Other (income) expense, net (238) (162) 47% (281) (151) 86% Income Before Taxes 6,745 4,090 65% 17,647 15,766 12% Income Tax Provision 958 929 2,346 2,377 Net Income 5,787 3,161 83% 15,301 13,389 14% Less: Net Income Attributable to Noncontrolling Interests 2 4 10 15 Net Income Attributable to Merck & Co., Inc., Rahway, N.J., USA 5,785 $ 3,157 $ 83% 15,291 $ 13,374 $ 14% Earnings per Common Share Assuming Dilution 2.32 $ 1.24 $ 87% 6.08 $ 5.26 $ 16% Average Shares Outstanding Assuming Dilution 2,498 2,541 2,514 2,543 Tax Rate 14.2% 22.7% 13.3% 15.1% * 100% or greater GAAP % Change 3Q25 3Q24 GAAP % Change Sep YTD 2025 Sep YTD 2024 MERCK & CO., INC., RAHWAY, N.J., USA CONSOLIDATED STATEMENT OF INCOME - GAAP (AMOUNTS IN MILLIONS, EXCEPT PER SHARE FIGURES) (UNAUDITED) Table 1 1 -- 2 of 10 -- Sales 15,529 $ 15,806 $ 17,276 $ 48,611 $ 15,775 $ 16,112 $ 16,657 $ 48,544 $ 15,624 $ 64,168 $ 4% 0% Costs, Expenses and Other Cost of sales 3,419 3,557 3,855 10,831 3,540 3,745 4,080 11,365 3,828 15,193 -6% -5% Selling, general and administrative 2,552 2,649 2,633 7,835 2,483 2,739 2,731 7,952 2,864 10,816 -4% -1% Research and development 3,621 4,048 4,234 11,903 3,992 3,500 5,862 13,354 4,585 17,938 -28% -11% Restructuring costs 69 560 47 676 123 80 56 258 51 309 -16% * Other (income) expense, net (35) (7) (238) (281) (33) 42 (162) (151) 126 (24) 47% 86% Income Before Taxes 5,903 4,999 6,745 17,647 5,670 6,006 4,090 15,766 4,170 19,936 65% 12% Income Tax Provision 818 571 958 2,346 903 545 929 2,377 425 2,803 Net Income 5,085 4,428 5,787 15,301 4,767 5,461 3,161 13,389 3,745 17,133 83% 14% Less: Net Income Attributable to Noncontrolling Interests 6 1 2 10 5 6 4 15 2 16 Net Income Attributable to Merck & Co., Inc., Rahway, N.J., USA 5,079 $ 4,427 $ 5,785 $ 15,291 $ 4,762 $ 5,455 $ 3,157 $ 13,374 $ 3,743 $ 17,117 $ 83% 14% Earnings per Common Share Assuming Dilution 2.01 $ 1.76 $ 2.32 $ 6.08 $ 1.87 $ 2.14 $ 1.24 $ 5.26 $ 1.48 $ 6.74 $ 87% 16% Average Shares Outstanding Assuming Dilution 2,531 2,513 2,498 2,514 2,544 2,544 2,541 2,543 2,537 2,541 Tax Rate 13.9% 11.4% 14.2% 13.3% 15.9% 9.1% 22.7% 15.1% 10.2% 14.1% * 100% or greater Sum of quarterly amounts may not equal year-to-date amounts due to rounding. Full Year 2025 2Q 3Q Sep YTD 1Q 1Q 2Q 3Q 2024 4Q 3Q Sep YTD % Change MERCK & CO., INC., RAHWAY, N.J., USA CONSOLIDATED STATEMENT OF INCOME - GAAP (AMOUNTS IN MILLIONS, EXCEPT PER SHARE FIGURES) (UNAUDITED) Table 1a Sep YTD 2 -- 3 of 10 -- Third Quarter Cost of sales 3,855 $ 621 110 731 3,124 $ Selling, general and administrative 2,633 34 34 2,599 Research and development 4,234 4 233 237 3,997 Restructuring costs 47 47 47 – Other (income) expense, net (238) (344) (344) 106 Income Before Taxes 6,745 (659) (390) 344 (705) 7,450 Income Tax Provision (Benefit) 958 (119) (3) (82) (3) 73 (3) 86 (4) (42) 1,000 Net Income 5,787 (540) (308) 271 (86) (663) 6,450 Net Income Attributable to Merck & Co., Inc., Rahway, N.J., USA 5,785 (540) (308) 271 (86) (663) 6,448 Earnings per Common Share Assuming Dilution 2.32 $ (0.22) (0.12) 0.11 (0.03) (0.26) 2.58 $ Tax Rate 14.2% 13.4% Sep YTD Cost of sales 10,831 $ 1,817 311 2,128 8,703 $ Selling, general and administrative 7,835 72 1 73 7,762 Research and development 11,903 14 286 300 11,603 Restructuring costs 676 676 676 – Other (income) expense, net (281) (3) (512) (515) 234 Income Before Taxes 17,647 (1,900) (1,274) 512 (2,662) 20,309 Income Tax Provision (Benefit) 2,346 (338) (3) (239) (3) 109 (3) (60) (4) (528) 2,874 Net Income 15,301 (1,562) (1,035) 403 60 (2,134) 17,435 Net Income Attributable to Merck & Co., Inc., Rahway, N.J., USA 15,291 (1,562) (1,035) 403 60 (2,134) 17,425 Earnings per Common Share Assuming Dilution 6.08 $ (0.62) (0.41) 0.16 0.02 (0.85) 6.93 $ Tax Rate 13.3% 14.2% Only the line items that are affected by non-GAAP adjustments are shown. GAAP Acquisition- and Divestiture-Related Costs (1) Restructuring Costs (2) (Income) Loss from Investments in Equity Securities Adjustment Subtotal Non-GAAP Certain Other Items MERCK & CO., INC., RAHWAY, N.J., USA THREE AND NINE MONTHS ENDED SEPTEMBER 30, 2025 GAAP TO NON-GAAP RECONCILIATION (AMOUNTS IN MILLIONS, EXCEPT PER SHARE FIGURES) (UNAUDITED) Table 2a The Company is providing certain non-GAAP information that excludes certain items because of the nature of these items and the impact they have on the analysis of underlying business performance and trends. Management believes that providing non-GAAP information enhances investors’ understanding of the Company’s results because management uses non-GAAP measures to assess performance. Management uses non-GAAP measures internally for planning and forecasting purposes and to measure the performance of the Company along with other metrics. In addition, annual employee compensation, including senior management’s compensation, is derived in part using a non-GAAP pretax income metric. The non-GAAP information presented should be considered in addition to, but not as a substitute for or superior to, information prepared in accordance with GAAP. (1) Amounts included in cost of sales for the third quarter reflect expenses for the amortization of intangible assets. Amounts included in cost of sales for the nine-month period include the amortization of intangible assets and intangible asset impairment charges, partially offset by a decrease in the estimated fair value measurement of liabilities for contingent consideration. Amounts included in selling, general and administrative expenses reflect integration, transaction and certain other costs related to acquisitions and divestitures. Amounts included in research and development expenses reflect the amortization of intangible assets. (2) Amounts primarily include employee separation costs, accelerated depreciation and asset impairments associated with facilities to be closed or divested, and contractual termination costs related to activities under the Company's formal restructuring programs. (3) Represents the estimated tax impacts on the reconciling items based on applying the statutory rate of the originating territory of the non-GAAP adjustments. (4) Amount in the third quarter represents tax expense relating to audit reserve adjustments. Amount in the nine-month period represents a tax benefit, including a net benefit related to favorable audit reserve adjustments. 3 -- 4 of 10 -- Third Quarter Cost of sales 4,080 $ 639 192 831 3,249 $ Selling, general and administrative 2,731 43 31 74 2,657 Research and development 5,862 24 24 5,838 Restructuring costs 56 56 56 – Other (income) expense, net (162) (27) 58 31 (193) Income Before Taxes 4,090 (679) (279) (58) (1,016) 5,106 Income Tax Provision (Benefit) 929 (129) (3) (46) (3) (13) (3) (188) 1,117 Net Income 3,161 (550) (233) (45) (828) 3,989 Net Income Attributable to Merck & Co., Inc., Rahway, N.J., USA 3,157 (550) (233) (45) (828) 3,985 Earnings per Common Share Assuming Dilution 1.24 $ (0.22) (0.09) (0.02) (0.33) 1.57 $ Tax Rate 22.7% 21.9% Sep YTD Cost of sales 11,365 $ 1,708 374 2,082 9,283 $ Selling, general and administrative 7,952 88 67 155 7,797 Research and development 13,354 60 2 62 13,292 Restructuring costs 258 258 258 – Other (income) expense, net (151) (48) (107) (155) 4 Income Before Taxes 15,766 (1,808) (701) 107 (2,402) 18,168 Income Tax Provision (Benefit) 2,377 (350) (3) (118) (3) 23 (3) (259) (4) (704) 3,081 Net Income 13,389 (1,458) (583) 84 259 (1,698) 15,087 Net Income Attributable to Merck & Co., Inc., Rahway, N.J., USA 13,374 (1,458) (583) 84 259 (1,698) 15,072 Earnings per Common Share Assuming Dilution 5.26 $ (0.57) (0.23) 0.03 0.10 (0.67) 5.93 $ Tax Rate 15.1% 17.0% Only the line items that are affected by non-GAAP adjustments are shown. GAAP Acquisition and Divestiture- Related Costs (1) Restructuring Costs (2) (Income) Loss from Investments in Equity Securities MERCK & CO., INC., RAHWAY, N.J., USA THREE AND NINE MONTHS ENDED SEPTEMBER 30, 2024 GAAP TO NON-GAAP RECONCILIATION (AMOUNTS IN MILLIONS, EXCEPT PER SHARE FIGURES) (UNAUDITED) Table 2b Non-GAAP Certain Other Items Adjustment Subtotal The Company is providing certain non-GAAP information that excludes certain items because of the nature of these items and the impact they have on the analysis of underlying business performance and trends. Management believes that providing non- GAAP information enhances investors’ understanding of the Company’s results because management uses non-GAAP measures to assess performance. Management uses non-GAAP measures internally for planning and forecasting purposes and to measure the performance of the Company along with other metrics. In addition, annual employee compensation, including senior management’s compensation, is derived in part using a non-GAAP pretax income metric. The non-GAAP information presented should be considered in addition to, but not as a substitute for or superior to, information prepared in accordance with GAAP. (1) Amounts included in cost of sales primarily reflect expenses for the amortization of intangible assets. Amounts included in selling, general and administrative expenses reflect integration, transaction and certain other costs related to acquisitions and divestitures. Amounts included in research and development expenses primarily reflect the amortization of intangible assets and Animal Health intangible asset impairment charges. Amounts included in other (income) expense, net, primarily reflect royalty income related to the prior termination of the Sanofi-Pasteur MSD joint venture. (2) Amounts primarily include employee separation costs, accelerated depreciation and asset impairments associated with facilities to be closed or divested related to activities under the Company's formal restructuring programs. (3) Represents the estimated tax impacts on the reconciling items based on applying the statutory rate of the originating territory of the non-GAAP adjustments. (4) Represents a benefit due to a reduction in reserves for unrecognized income tax benefits resulting from the expiration of the statute of limitations for assessments related to the 2019 federal tax return year. 4 -- 5 of 10 -- MERCK & CO., INC., RAHWAY, N.J., USA FRANCHISE / KEY PRODUCT SALES (AMOUNTS IN MILLIONS) (UNAUDITED) Table 3 2025 2024 3Q Sep YTD 1Q 2Q 3Q Sep YTD 1Q 2Q 3Q Sep YTD 4Q Full Year Nom % Ex-Exch % Nom % Ex-Exch % TOTAL SALES (1) $15,529 $15,806 $17,276 $48,611 $15,775 $16,112 $16,657 $48,544 $15,624 $64,168 4 3 0 1 PHARMACEUTICAL 13,638 14,050 15,611 43,299 14,006 14,408 14,943 43,358 14,042 57,400 4 3 0 0 Oncology Keytruda 7,205 7,956 8,142 23,303 6,947 7,270 7,429 21,646 7,836 29,482 10 8 8 8 Alliance Revenue – Lynparza (2) 312 370 379 1,061 292 317 337 947 365 1,311 12 12 12 12 Alliance Revenue – Lenvima (2) 258 265 258 781 255 249 251 755 255 1,010 3 2 3 3 Welireg 137 162 196 496 85 126 139 349 160 509 42 41 42 42 Alliance Revenue – Reblozyl (3) 119 107 136 361 71 90 100 261 110 371 36 36 39 39 Vaccines (4) Gardasil/Gardasil 9 1,327 1,126 1,749 4,202 2,249 2,478 2,306 7,032 1,550 8,583 -24 -25 -40 -40 ProQuad/M-M-R II/Varivax 539 609 684 1,832 570 617 703 1,891 594 2,485 -3 -3 -3 -3 Vaxneuvance 230 229 226 685 219 189 239 647 161 808 -6 -7 6 6 RotaTeq 228 121 204 554 216 163 193 572 139 711 6 5 -3 -3 Capvaxive 107 129 244 480 47 47 50 97 * * * * Pneumovax 23 41 38 45 124 61 59 68 188 74 263 -34 -35 -34 -34 Hospital Acute Care Bridion 441 461 439 1,341 440 455 420 1,315 449 1,764 5 4 2 2 Prevymis 208 228 266 702 174 188 208 570 215 785 28 25 23 23 Zerbaxa 70 74 81 225 56 62 64 182 70 252 25 24 24 24 Dificid 83 96 43 222 73 92 96 261 79 340 -55 -55 -15 -15 Cardiovascular Winrevair 280 336 360 976 70 149 219 200 419 141 141 * * Alliance Revenue - Adempas/Verquvo (5) 106 123 112 340 98 106 102 306 109 415 9 9 11 11 Adempas (6) 68 80 82 229 70 72 72 214 73 287 14 7 7 5 Virology Lagevrio 102 83 138 323 350 110 383 843 121 964 -64 -65 -62 -62 Isentress/Isentress HD 90 86 82 258 111 89 102 302 92 394 -20 -21 -15 -14 Delstrigo 67 83 77 228 56 60 65 180 69 249 19 13 26 24 Pifeltro 45 41 43 128 42 39 42 123 40 163 1 -1 4 4 Neuroscience Belsomra 50 40 47 137 46 53 78 177 45 222 -40 -40 -23 -22 Immunology Simponi 184 172 189 545 543 -100 -100 -100 -100 Remicade 39 35 41 115 114 -100 -100 -100 -100 Diabetes (7) Januvia 549 372 382 1,302 419 405 278 1,102 232 1,334 37 37 18 19 Janumet 247 251 243 741 251 224 204 679 255 935 19 20 9 11 Other Pharmaceutical (8) 729 584 953 2,268 632 618 638 1,890 699 2,590 50 49 20 21 ANIMAL HEALTH 1,588 1,646 1,615 4,849 1,511 1,482 1,487 4,480 1,397 5,877 9 7 8 10 Livestock 924 961 1,023 2,909 850 837 886 2,573 889 3,462 16 14 13 15 Companion Animal 664 685 592 1,940 661 645 601 1,907 508 2,415 -2 -3 2 2 Other Revenues (9) 303 110 50 463 258 222 227 706 185 891 -78 -27 -34 -4 *200% or greater Sum of quarterly amounts may not equal year-to-date amounts due to rounding. (7) Total Diabetes sales were $876 million, $704 million and $703 million in the first, second and third quarter of 2025, respectively, and $745 million, $715 million and $592 million in the first, second and third quarter of 2024. (8) Includes Pharmaceutical products not individually shown above. Also reflects total alliance revenue for Koselugo of $44 million, $43 million and $214 million in the first, second and third quarter of 2025, respectively, and $38 million, $37 million and $39 million in the first, second and third quarter of 2024, respectively. (9) Other Revenues are comprised primarily of revenues from third-party manufacturing arrangements and miscellaneous corporate revenues, including revenue-hedging activities. Other Revenues related to the receipt of upfront and milestone payments for out-licensed products were $95 million, $5 million and $11 million in the first, second and third quarter of 2025, respectively, and $61 million, $15 million and $15 million in the first, second and third quarter of 2024, respectively. (1) Only select products are shown. (2) Alliance Revenue represents the Company's share of profits, which are product sales net of cost of sales and commercialization costs. (3) Alliance Revenue represents royalties. (4) Total Vaccines sales were $2,607 million, $2,370 million and $3,370 million in the first, second and third quarter of 2025, respectively, and $3,424 million, $3,656 million and $3,675 million in the first, second and third quarter of 2024, respectively. (5) Alliance Revenue represents the Company's share of profits from sales in Bayer's marketing territories, which are product sales net of cost of sales and commercialization costs. (6) Net product sales in the Company's marketing territories. 5 -- 6 of 10 -- MERCK & CO., INC., RAHWAY, N.J., USA FRANCHISE / KEY PRODUCT SALES THIRD QUARTER 2025 (AMOUNTS IN MILLIONS) (UNAUDITED) Table 3a Global U.S. International 3Q 2025 3Q 2024 % Change 3Q 2025 3Q 2024 % Change 3Q 2025 3Q 2024 % Change TOTAL SALES (1) $17,276 $16,657 4 $10,012 $8,736 15 $7,264 $7,922 -8 PHARMACEUTICAL 15,611 14,943 4 9,493 8,227 15 6,118 6,717 -9 Oncology Keytruda 8,142 7,429 10 4,879 4,500 8 3,263 2,929 11 Alliance Revenue – Lynparza (2) 379 337 12 184 161 14 195 177 11 Alliance Revenue – Lenvima (2) 258 251 3 177 173 2 81 78 4 Welireg 196 139 42 161 127 27 35 12 196 Alliance Revenue – Reblozyl (3) 136 100 36 111 82 35 25 18 40 Vaccines (4) Gardasil/Gardasil 9 1,749 2,306 -24 1,154 1,020 13 595 1,285 -54 ProQuad/M-M-R II/Varivax 684 703 -3 554 572 -3 130 131 -1 Capvaxive 244 47 * 238 47 * 7 0 * Vaxneuvance 226 239 -6 134 137 -1 91 103 -11 RotaTeq 204 193 6 141 131 8 63 62 2 Pneumovax 23 45 68 -34 10 19 -48 35 49 -28 Hospital Acute Care Bridion 439 420 5 392 339 15 47 81 -42 Prevymis 266 208 28 128 101 27 138 107 29 Zerbaxa 81 64 25 49 39 25 32 26 25 Dificid 43 96 -55 30 83 -64 13 13 -2 Cardiovascular Winrevair 360 149 141 335 147 129 25 3 * Alliance Revenue - Adempas/Verquvo (5) 112 102 9 103 96 8 8 7 25 Adempas (6) 82 72 14 82 72 14 Virology Lagevrio 138 383 -64 24 84 -71 114 299 -62 Isentress/Isentress HD 82 102 -20 44 54 -18 37 48 -23 Delstrigo 77 65 19 13 15 -13 64 50 29 Pifeltro 43 42 1 29 31 -7 14 12 21 Neuroscience Belsomra 47 78 -40 28 20 40 19 58 -67 Immunology Simponi 189 -100 189 -100 Remicade 41 -100 41 -100 Diabetes (7) Januvia 382 278 37 258 67 * 124 211 -42 Janumet 243 204 19 78 15 * 165 190 -13 Other Pharmaceutical (8) 953 638 50 239 167 43 716 466 54 ANIMAL HEALTH 1,615 1,487 9 504 487 3 1,112 999 11 Livestock 1,023 886 16 213 194 10 811 692 17 Companion Animal 592 601 -2 291 293 -1 301 307 -2 Other Revenues (9) 50 227 -78 15 22 -32 34 206 -83 *200% or greater (6) Net product sales in the Company's marketing territories. (7) Total Diabetes sales were $703 million and $592 million on a global basis in the third quarter of 2025 and 2024, respectively. (8) Includes Pharmaceutical products not individually shown above. Also reflects total alliance revenue for Koselugo of $214 million and $39 million on a global basis in the third quarter of 2025 and 2024, respectively. (9) Other Revenues are comprised primarily of revenues from third-party manufacturing arrangements and miscellaneous corporate revenues, including revenue-hedging activities. Other Revenues related to the receipt of upfront and milestone payments for out-licensed products were $11 million and $15 million in the third quarter of 2025 and 2024, respectively. Sum of U.S. plus international may not equal global due to rounding. (1) Only select products are shown. (2) Alliance Revenue represents the Company's share of profits, which are product sales net of cost of sales and commercialization costs. (3) Alliance Revenue represents royalties. (4) Total Vaccines sales were $3,370 million and $3,675 million on a global basis in the third quarter of 2025 and 2024, respectively. (5) Alliance Revenue represents the Company's share of profits from sales in Bayer's marketing territories, which are product sales net of cost of sales and commercialization costs. 6 -- 7 of 10 -- MERCK & CO., INC., RAHWAY, N.J., USA FRANCHISE / KEY PRODUCT SALES SEPTEMBER YEAR-TO-DATE 2025 (AMOUNTS IN MILLIONS) (UNAUDITED) Table 3b Global U.S. International Sep YTD 2025 Sep YTD 2024 % Change Sep YTD 2025 Sep YTD 2024 % Change Sep YTD 2025 Sep YTD 2024 % Change TOTAL SALES (1) $48,611 $48,544 0 $27,371 $24,089 14 $21,240 $24,455 -13 PHARMACEUTICAL 43,299 43,358 0 25,747 22,563 14 17,552 20,795 -16 Oncology Keytruda 23,303 21,646 8 13,936 13,031 7 9,367 8,614 9 Alliance Revenue – Lynparza (2) 1,061 947 12 503 449 12 558 498 12 Alliance Revenue – Lenvima (2) 781 755 3 545 523 4 236 233 2 Welireg 496 349 42 422 320 32 74 29 157 Alliance Revenue – Reblozyl (3) 361 261 39 299 215 39 62 45 37 Vaccines (4) Gardasil/Gardasil 9 4,202 7,032 -40 2,235 2,045 9 1,967 4,988 -61 ProQuad/M-M-R II/Varivax 1,832 1,891 -3 1,457 1,500 -3 374 391 -4 Vaxneuvance 685 647 6 409 397 3 276 251 10 RotaTeq 554 572 -3 366 388 -6 187 185 2 Capvaxive 480 47 * 473 47 * 8 0 * Pneumovax 23 124 188 -34 13 36 -63 111 152 -27 Hospital Acute Care Bridion 1,341 1,315 2 1,181 1,020 16 161 296 -46 Prevymis 702 570 23 345 265 30 357 305 17 Zerbaxa 225 182 24 136 106 29 89 77 16 Dificid 222 261 -15 185 231 -20 37 30 21 Cardiovascular Winrevair 976 219 * 926 216 * 49 3 * Alliance Revenue - Adempas/Verquvo (5) 340 306 11 308 283 9 32 22 43 Adempas (6) 229 214 7 229 214 7 Virology Lagevrio 323 843 -62 90 144 -38 233 699 -67 Isentress/Isentress HD 258 302 -15 144 147 -2 114 155 -26 Delstrigo 228 180 26 42 42 1 185 139 33 Pifeltro 128 123 4 86 86 -1 43 37 16 Neuroscience Belsomra 137 177 -23 59 53 12 77 124 -38 Immunology Simponi 545 -100 545 -100 Remicade 115 -100 115 -100 Diabetes (7) Januvia 1,302 1,102 18 819 428 91 483 674 -28 Janumet 741 679 9 210 70 * 530 610 -13 Other Pharmaceutical (8) 2,268 1,890 20 558 521 7 1,713 1,364 26 ANIMAL HEALTH 4,849 4,480 8 1,505 1,417 6 3,345 3,063 9 Livestock 2,909 2,573 13 598 529 13 2,312 2,044 13 Companion Animal 1,940 1,907 2 907 888 2 1,033 1,019 1 Other Revenues (9) 463 706 -34 119 109 9 343 597 -43 *200% or greater (6) Net product sales in the Company's marketing territories. (7) Total Diabetes sales were $2,283 million and $2,053 million on a global basis for September YTD 2025 and 2024, respectively. (8) Includes Pharmaceutical products not individually shown above. Also reflects total alliance revenue for Koselugo of $301 million and $114 million on a global basis for September YTD 2025 and 2024, respectively. (9) Other Revenues are comprised primarily of revenues from third-party manufacturing arrangements and miscellaneous corporate revenues, including revenue-hedging activities. Other Revenues related to the receipt of upfront and milestone payments for out-licensed products were $111 million and $91 million on a global basis for September YTD 2025 and 2024, respectively. Sum of U.S. plus international may not equal global due to rounding. (1) Only select products are shown. (2) Alliance Revenue represents the Company's share of profits, which are product sales net of cost of sales and commercialization costs. (3) Alliance Revenue represents royalties. (4) Total Vaccines sales were $8,347 million and $10,755 million on a global basis for September YTD 2025 and 2024, respectively. (5) Alliance Revenue represents the Company's share of profits from sales in Bayer's marketing territories, which are product sales net of cost of sales and commercialization costs. 7 -- 8 of 10 -- MERCK & CO., INC., RAHWAY, N.J., USA PHARMACEUTICAL GEOGRAPHIC SALES (AMOUNTS IN MILLIONS) (UNAUDITED) Table 3c 2025 2024 % Change 1Q 2Q 3Q Sep YTD 1Q 2Q 3Q Sep YTD 4Q Full Year 3Q Sep YTD TOTAL PHARMACEUTICAL $13,638 $14,050 $15,611 $43,299 $14,006 $14,408 $14,943 $43,358 $14,042 $57,400 4 0 United States 7,927 8,328 9,493 25,747 6,936 7,399 8,227 22,563 7,728 30,290 15 14 % Pharmaceutical Sales 58.1% 59.3% 60.8% 59.5% 49.5% 51.4% 55.1% 52.0% 55.0% 52.8% Europe (1) 2,384 2,551 2,675 7,610 2,555 2,572 2,620 7,748 2,498 10,246 2 -2 % Pharmaceutical Sales 17.5% 18.2% 17.1% 17.6% 18.2% 17.9% 17.5% 17.9% 17.8% 17.9% Japan 651 604 693 1,948 802 664 919 2,386 813 3,199 -25 -18 % Pharmaceutical Sales 4.8% 4.3% 4.4% 4.5% 5.7% 4.6% 6.2% 5.5% 5.8% 5.6% Latin America 589 654 691 1,933 601 661 730 1,992 680 2,672 -5 -3 % Pharmaceutical Sales 4.3% 4.7% 4.4% 4.5% 4.3% 4.6% 4.9% 4.6% 4.8% 4.7% Asia Pacific (other than China and Japan) 535 609 593 1,736 580 595 669 1,844 612 2,457 -11 -6 % Pharmaceutical Sales 3.9% 4.3% 3.8% 4.0% 4.1% 4.1% 4.5% 4.3% 4.4% 4.3% China (2) 668 407 377 1,452 1,744 1,790 996 4,530 864 5,394 -62 -68 % Pharmaceutical Sales 4.9% 2.9% 2.4% 3.4% 12.5% 12.4% 6.7% 10.4% 6.2% 9.4% Eastern Europe/Middle East/Africa 435 451 365 1,250 395 353 400 1,147 348 1,495 -9 9 % Pharmaceutical Sales 3.2% 3.2% 2.3% 2.9% 2.8% 2.4% 2.7% 2.6% 2.5% 2.6% Canada 125 135 134 394 138 143 133 414 144 558 1 -5 % Pharmaceutical Sales 0.9% 1.0% 0.9% 0.9% 1.0% 1.0% 0.9% 1.0% 1.0% 1.0% Other 324 311 590 1,229 255 231 249 734 355 1,089 137 67 % Pharmaceutical Sales 2.4% 2.1% 3.9% 2.7% 1.9% 1.6% 1.5% 1.7% 2.5% 1.7% Sum of quarterly amounts may not equal year-to-date amounts due to rounding. (1) Europe represents all European Union countries, the European Union accession markets and the United Kingdom. (2) Gardasil/Gardasil 9 sales in China were $193 million, $0 and $0 in the first, second and third quarter of 2025, respectively, and $1,253 million, $1,312 million, $517 million and $446 million in the first, second, third and fourth quarter of 2024, respectively. 8 -- 9 of 10 -- OTHER (INCOME) EXPENSE, NET 3Q25 3Q24 Sep YTD 2025 Sep YTD 2024 Interest income (96) $ (127) $ (274) $ (269) $ Interest expense 327 330 946 943 Exchange losses 56 33 224 177 (Income) loss from investments in equity securities, net (1) (373) 31 (563) (169) Net periodic defined benefit plan (credit) cost other than service cost (152) (157) (452) (476) Other, net - (272) (162) (357) Total (238) $ (162) $ (281) $ (151) $ (1) Includes net realized and unrealized gains and losses from investments in equity securities either owned directly or through ownership interests in investment funds. Unrealized gains and losses from investments that are directly owned are determined at the end of the reporting period, while gains and losses from ownership interests in investment funds are accounted for on a one quarter lag. MERCK & CO., INC., RAHWAY, N.J., USA OTHER (INCOME) EXPENSE, NET - GAAP (AMOUNTS IN MILLIONS) (UNAUDITED) Table 4 9 -- 10 of 10 --